Search Results 581-590 of 17383 for alopecia

1. A Study to Assess Clonal Diversity of Freshly Taken ESD Specimens - Mayo Clinic

   Inclusion Criteria: Patients with Barrett's Esophagus (BE) or Esophageal Adenocarcinoma (EAC) that are planned for Endoscopic Submucosal Dissection (ESD) ...

2. Study of MK-8242 Alone and in Combination with Cytarabine in Participants with Acute Myelogenous Leukemia (P07649) - Mayo Clinic

   Recovered from the effects of any prior surgery, radiotherapy or anti-neoplastic treatment, with the exception of alopecia; Must be able to swallow, retain ...

3. A Study of SC‑004 in Subjects With Advanced Solid Tumors - Mayo Clinic

   Recovery to Grade 1 of any clinically significant toxicity (excluding alopecia) prior to initiation of study drug administration. Satisfactory laboratory ...

4. Phase 3 Study of T-DXd and Rilvegostomig versus SoC in Advanced HER2-expressing Biliary Tract Cancer - Mayo Clinic

   Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to Grade ≤ 1 or baseline. Note ...

5. Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients With Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer - Mayo Clinic

   ... alopecia and sensory neuropathy grade ≤ 2 is acceptable. Known severe (grade ≥ 3 NCI-CTCAE v5.0) hypersensitivity reactions to monoclonal antibodies, or ...

6. Psoriasis - Doctors and departments - Mayo Clinic

   Learn about this common skin condition that causes red, scaly, itchy patches and how you can combine medications with self-care habits to manage it.

7. A Study of AO-176 as Monotherapy Combinated with Bortezomib and Dexamethasone in Adults with Relapsed or Refractory Multiple Myeloma - Mayo Clinic

   Resolution of prior therapy-related AEs (including immune-related AEs but excluding alopecia) to ≤ Grade 1 (except for Grade 2 peripheral neuropathy) per CTCAE ...

8. Study of TJ011133 in Participants With Relapsed/ Refractory Advanced Solid Tumors and Lymphoma - Mayo Clinic

   Not recovered (i.e., to ≤ Grade 1 or to baseline) from AEs emerging from previous treatments (except alopecia or neuropathy). Incomplete recovery from AEs ...

9. Clinical Trials - Study of bb2121 in Multiple Myeloma

   Recovery to ≤ Grade 1 or baseline of any non-hematologic toxicities due to prior treatments, excluding alopecia and Grade 2 neuropathy. * True abstinence ...

10. A Study to Evaluate CC-98633 to Treat Subjects with Relapsed and/or Refractory Multiple Myeloma - Mayo Clinic

    Recovery to ≤ Grade 1 or baseline of any non-hematological toxicities due to previous therapy, except alopecia and peripheral neuropathy. Agree to refrain ...